Santen Pharmaceutical Co Ltd (SNPHY)
OTHER OTC:SNPHY
Want to see SNPHY full AI Analyst Report?
Top Page
Santen Pharmaceutical Co
(OTC:SNPHY)
Select Model
Select Model
Rating:76Outperform
Price Target:
$13.50
▲(22.73% Upside)
Action:Upgraded
Date:05/17/26
The score is driven primarily by solid financial performance, led by a strong, debt-free balance sheet and recovered profitability, partially offset by historical earnings and cash-flow volatility. Technicals are supportive with the stock trading above major moving averages and a positive MACD, though overbought signals add near-term risk. Valuation appears reasonable with a moderate P/E and a modest dividend yield.
Positive Factors
Focused ophthalmology franchise
A concentrated specialist model in ophthalmology creates durable revenue from prescription therapies and recurring patient demand. Clinical expertise and focused R&D increase barriers to entry, supporting steady product adoption and longer lifecycle earnings versus commodity drug makers.
Negative Factors
Earnings and cash-flow volatility
Historic swings (including a 2023 loss) and variability in results make multi-quarter forecasting and planning harder. Volatile earnings can limit consistent R&D spending, dividend policy predictability, and investor confidence, increasing execution risk over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Focused ophthalmology franchise
A concentrated specialist model in ophthalmology creates durable revenue from prescription therapies and recurring patient demand. Clinical expertise and focused R&D increase barriers to entry, supporting steady product adoption and longer lifecycle earnings versus commodity drug makers.
Read all positive factors
Santen Pharmaceutical Co (SNPHY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.85B
Dividend Yield2.02%
Average Volume (3M)1.01K
Price to Earnings (P/E)14.6
Beta (1Y)-0.03
Revenue Growth-1.78%
EPS Growth9.97%
CountryUS
Employees3,744
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - General
Share Statistics
EPS (TTM)116.58
Shares Outstanding322,290,160
10 Day Avg. Volume2,904
30 Day Avg. Volume1,010
Financial Highlights & Ratios
PEG Ratio0.87
Price to Book (P/B)1.94
Price to Sales (P/S)1.87
P/FCF Ratio14.88
Enterprise Value/Market Cap139.32
Enterprise Value/Revenue1.81
Enterprise Value/Gross Profit3.24
Enterprise Value/Ebitda8.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Santen Pharmaceutical Co Business Overview & Revenue Model
Company Description
Santen Pharmaceutical Co., Ltd. researches and develops, manufactures, and markets pharmaceuticals and medical devices in Japan and internationally. It offers various pharmaceutical products to treat glaucoma and ocular hypertension, such as DE-11...
How the Company Makes Money
Santen primarily makes money by selling ophthalmic pharmaceuticals, with revenue largely generated from prescription products. Its key revenue streams come from (1) sales of branded ophthalmic drugs (notably therapies for glaucoma/ocular hypertens...
Santen Pharmaceutical Co Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
86
Very Positive
Cash Flow
67
Positive
| Breakdown | Mar 2026 | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 309.21B | 300.00B | 301.96B | 279.04B | 266.26B |
| Gross Profit | 170.68B | 171.03B | 178.71B | 166.09B | 156.59B |
| EBITDA | 67.41B | 59.01B | 50.72B | 12.95B | 52.93B |
| Net Income | 39.62B | 36.26B | 26.64B | -14.95B | 27.22B |
Balance Sheet | |||||
| Total Assets | 424.87B | 409.28B | 435.70B | 421.18B | 459.98B |
| Cash, Cash Equivalents and Short-Term Investments | 81.23B | 93.99B | 94.96B | 58.68B | 84.31B |
| Total Debt | 0.00 | 34.23B | 35.16B | 36.21B | 32.93B |
| Total Liabilities | 127.57B | 124.10B | 130.33B | 127.88B | 123.13B |
| Stockholders Equity | 298.28B | 286.24B | 306.06B | 293.98B | 337.49B |
Cash Flow | |||||
| Free Cash Flow | 38.87B | 54.27B | 61.96B | 12.56B | 10.20B |
| Operating Cash Flow | 46.12B | 60.93B | 72.65B | 37.15B | 46.04B |
| Investing Cash Flow | -13.76B | -8.22B | -6.14B | -26.78B | -35.17B |
| Financing Cash Flow | -52.32B | -53.31B | -34.03B | -37.22B | 5.56B |
Santen Pharmaceutical Co Technical Analysis
Positive
11.00
Price Trends
10.97
Positive
10.94
Positive
10.69
Positive
Market Momentum
0.26
Negative
62.86
Neutral
97.58
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNPHY, the sentiment is Positive. The current price of 11 is above the 20-day moving average (MA) of 10.86, above the 50-day MA of 10.97, and above the 200-day MA of 10.69, indicating a bullish trend. The MACD of 0.26 indicates Negative momentum. The RSI at 62.86 is Neutral, neither overbought nor oversold. The STOCH value of 97.58 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNPHY.
Santen Pharmaceutical Co Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | $3.85B | 14.59 | 13.15% | 2.02% | -1.78% | 9.97% | |
71 Outperform | $119.54B | 11.57 | 39.05% | 4.11% | 1.78% | 33.76% | |
71 Outperform | £216.34B | 24.41 | 22.41% | 1.53% | 4.64% | 26.75% | |
69 Neutral | $107.18B | 15.55 | 14.41% | 4.58% | 11.19% | -0.23% | |
66 Neutral | $101.71B | 12.08 | 35.78% | 3.41% | 9.19% | 98.98% | |
59 Neutral | $6.79B | 15.91 | 7.88% | 1.56% | 8.91% | 129.84% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
SNPHY
Santen Pharmaceutical Co
11.83
0.83
7.54%
BMY
Bristol-Myers Squibb
59.55
14.76
32.95%
GSK
GlaxoSmithKline
51.53
14.00
37.31%
GRFS
Grifols SA
8.11
0.09
1.12%
SNY
Sanofi
44.92
-5.58
-11.04%
GB:AZN
AstraZeneca
14,006.00
3,809.71
37.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.